RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0041-1729495
Ovarian Tissue Reservation and Risk of Reimplantation in a Young Girl with Acute Lymphocytic Leukemia after 6-Month Chemotherapy: A Case Report
Abstract
In the fertility preservation programs, ovarian cryopreservation is usually offered when the risk of premature ovarian failure is high (>30–50%) while the risk of ovarian metastasis is low. According to the guidelines, it must be done before the patient receives chemotherapy. A 22-year-old girl with acute lymphocytic leukemia was a candidate for ovarian cryopreservation after 6 months of chemotherapy. Despite chemotherapy, the anti-Mullerian hormone survey was within normal range. Ovarian tissue cryopreservation was done. In the histology survey, follicular density was 7.48. This case shows that only having a history of chemotherapy does not exclude the patient from the fertility preservation program. Regarding referring the patients for fertility preservation, cumulative factors such as a history of gonadotoxic treatment, age, and treatment protocol should be considered. In addition, the case was negative for assessing of CD45 marker. New data may challenge previous strict criteria, and extend the indications of this effective method in preserving fertility among cancer patients.
Publikationsverlauf
Artikel online veröffentlicht:
25. Juli 2021
© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India
-
References
- 1 Revel A, Revel-Vilk S. Fertility preservation in young cancer patients. J Hum Reprod Sci 2010; 3 (01) 2-7
- 2 Font-Gonzalez A, Mulder RL, Loeffen EAH. et al. PanCareLIFE Consortium. Fertility preservation in children, adolescents, and young adults with cancer: quality of clinical practice guidelines and variations in recommendations. Cancer 2016; 122 (14) 2216-2223
- 3 Wallace WHB, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered?. Lancet Oncol 2005; 6 (04) 209-218
- 4 Backhus LE, Kondapalli LA, Chang RJ, Coutifaris Ch, Kazer R, Woodruff TK. Oncofertility consortium consensus statement: guidelines for ovarian tissue cryopreservation. Cancer Treat Res 2007; 138: 235-239
- 5 Gracia CR. Reproductive health after cancer. Cancer Treat Res 2010; 156: 3-9
- 6 Wallace WHB, Smith AG, Kelsey TW, Edgar AE, Anderson RA. Fertility preservation for girls and young women with cancer: population-based validation of criteria for ovarian tissue cryopreservation. Lancet Oncol 2014; 15 (10) 1129-1136
- 7 von Wolff M, Montag M, Dittrich R, Denschlag D, Nawroth F, Lawrenz B. Fertility preservation in women–a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin’s lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet 2011; 284 (02) 427-435
- 8 Mahajan N. Fertility preservation in female cancer patients: an overview. J Hum Reprod Sci 2015; 8 (01) 3-13
- 9 Meirow D, Ra’anani H, Shapira M, Brenghausen M, Chaim SD, Aviel-Ronen S. et al. Transplantations of frozen-thawed ovarian tissue demonstrate high reproductive performance and the need to revise restrictive criteria. Fertility and sterility 2016; 106 (02) 467-474